It has been reported that PSME3 plays oncogenic roles in pancreatic cancer by mediating c-Myc degradation to accelerate glycolysis and might act as a new therapeutic target for pancreatic cancer (Guo et al., 2017). The gene discussed is MYC; the disease is familial pancreatic carcinoma.